株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のポイントオブケア(POC)診断市場

Point of Care Diagnostics

発行 BCC Research 商品コード 228049
出版日 ページ情報 英文 220 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
世界のポイントオブケア(POC)診断市場 Point of Care Diagnostics
出版日: 2016年11月07日 ページ情報: 英文 220 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

2015年に180億米ドルを記録した世界におけるポイントオブケア(POC)診断市場は、2016年には193億米ドルに達する見通しです。また、同市場は今後5年間のCAGRが8.0%で拡大し、2021年には283億米ドルとなる見込みです。

当レポートでは、世界におけるポイントオブケア(POC)診断市場の現状と将来予測、成長への影響因子や課題、主要参入企業のプロファイルなどを提供しております。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • POC検査とは?
  • 業界用語
  • POC市場概要
  • 臨床診断の一環としてのPOCの業界構造
  • POC検査の実施場所
  • 一般的なPOC検査
  • 米国におけるCLIAの重要性
  • POC検査におけるFDAの役割
  • POC市場の発展要因
  • 薬物乱用に関する注目

第4章 世界のPOC市場

  • 市場概要
  • 競合他社の市場シェア
  • 市場構造
    • 流通
    • プロモーション
    • 戦略的アライアンス・合併
  • 市場コンポーネント
    • 血液化学・電解質検査
    • 心臓マーカー検査
    • コレステロール検査
    • 薬物・アルコール中毒検査
    • 血糖値検査
    • 感染症検査
    • 妊娠・受胎能試験
    • 血液学的/血液凝固能検査
    • 腫瘍マーカー検査
    • 尿化学検査
    • MISC検査

第5章 血液化学・電解質検査

  • セグメントの概要
  • 血液化学パラメーター
  • 市場規模
  • 市場参入企業・市場シェア

第6章 心臓マーカー検査

  • セグメント概要
  • 市場規模
  • 市場参入企業・市場シェア

第7章 コレステロール検査

第8章 薬物・アルコール中毒検査

第9章 血糖値検査

第10章 感染症検査

第11章 妊娠・受胎能試験

第12章 ヘモグロビン/止血検査

第13章 腫瘍マーカー検査

第14章 尿化学検査

第15章 その他のPOC検査

第16章 技術アプリケーション

第17章 世界のPOC市場

  • 国際市場の規模
  • 世界市場のシェア
  • 世界市場におけるメーカーのプレゼンス

第18章 主な市場参入企業のプロファイル

  • 市場参入企業の概要
  • 企業プロファイル

第19章 付録

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: HLC043E

The global point of care (POC) diagnostics market was valued at nearly $16.8 billion and $18.0 billion in 2014 and 2015, respectively. This market is expected to grow from $19.3 billion in 2016 to $28.3 billion in 2021 at a compound annual growth rate (CAGR) of 8.0% for 2016-2021.

This report provides:

  • An overview of the global markets for point of care diagnostics.
  • Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Discussion of factors driving the market including staff shortages, older populations, long-term cost savings, and need for faster diagnosis and care.
  • A look at how availability of POC testing has revolutionized the continuum of the patient-care process.
  • In depth analysis of the major force driving the growth of this industry, the effort to provide better patient care by improving the turn-around-time (TAT) that POC testing offers.
  • A look at the other market factors including growth restraints and opportunities.
  • Profiles of major players in the industry.

image1

REPORT SCOPE

SCOPE OF REPORT

This study will describe the market for POC diagnostics at the global level. It focuses on the accelerating growth in this important diagnostic market segment and the key industry players. Specifically, the report:

  • Describes the POC industry.
  • Estimates the current and future market size.
  • Provides breakdowns for U.S. markets.
  • Describes product segments and the continuous updating of POC products.
  • Analyzes market influences in the industry and predicts the changes that will shape the future POC market.
  • Discusses trends within the market and provides a future outlook.
  • Reviews business activities of market leaders.
  • Lists patents for POC technologies.

ANALYST'S CREDENTIALS

Jon Evans has been involved in business development and research for the medical industry since 1984. Mr. Evans' career includes four years as a diagnostic systems sales representative and more than 15 years in market research and strategy analysis with Fortune 500 clients. He has developed expertise in assessing the unique business development challenges facing firms in the medical industry and designing strategies to optimize market performance. Mr. Evans received a B.S. in biology from Rutgers University in 1983, and an MBA in business analysis from San Francisco State University in 1989.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTION OF THE STUDY AND FOR WHOM
  • SCOPE OF REPORT
  • DEFINING POC
  • METHODOLOGY
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • OVERVIEW
  • MAJOR FINDINGS
  • SUMMARY TABLE GLOBAL POC MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL POC MARKET, BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 3 INDUSTRY OVERVIEW

  • WHAT IS POC TESTING?
  • INDUSTRY TERMS[1]
  • OVERVIEW OF THE POC MARKET
  • POC AS PART OF CLINICAL DIAGNOSTICS INDUSTRY STRUCTURE
    • MEDICAL BENEFITS DERIVED FROM IMMEDIATE DIAGNOSTIC TESTING
  • POC TESTING SITES
  • TABLE 1 SELECTED KEY STATISTICS FOR POC TESTING SITES
    • HOME USE/SELF-CARE
    • EMERGENCY ROOMS
    • CRITICAL-CARE UNITS
    • BEDSIDE TESTING
    • TABLE 2 ESTIMATED NUMBER OF HOSPITALS/INPATIENT ACUTE CARE CENTERS AND BEDS AVAILABLE BY SELECTED COUNTRY, 2016
    • FIGURE 1 ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE BEDS BY SELECTED COUNTRY, 2016
    • OPERATING ROOMS/PROCEDURE ROOMS
    • PHYSICIANS OFFICES/CLINICS/TREATMENT CENTERS/OTHER NONCRITICAL-CARE SITES
    • Nursing Homes and Hospice
    • TABLE 3 ESTIMATED NURSING HOMES RESIDENTS BY SELECTED U.S. STATES, 2016 (NO./%)
    • TABLE 4 HOSPICE FACTS, 2016 ESTIMATED
  • POC PRODUCT SEGMENTS
    • POC CLINICAL ASSAY CATEGORIES
      • Blood Chemistry and Electrolytes
      • Cardiac Marker
      • Cholesterol Testing/Monitoring
      • Drug and Alcohol Screening
      • Glucose Testing and Monitoring
      • Infectious Disease Testing
      • Pregnancy and Fertility Testing
      • Hemoglobin and Hemostasis
      • Tumor Marker
      • Urinalysis/Urine Chemistry
  • COMMONLY PERFORMED POC TESTS
  • TABLE 5 SELECTED POC TESTS-CLIA WAIVED
  • SIGNIFICANCE OF CLIA IN THE UNITED STATES
  • THE FDA'S ROLE IN POC TESTING
    • GOOD MANUFACTURING PRACTICE
    • TABLE 6 PERTINENT PARAMETERS OF GMP REGULATIONS AFFECTING IN VITRO DIAGNOSTICS
  • DRIVING FORCES OF THE POC MARKET
    • COST CONTAINMENT
      • Rising Healthcare Costs
      • TABLE 7 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY SELECT COUNTRY. 1980-2015 (%)
      • FIGURE 2 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY SELECT COUNTRY, 1980-2015 (%)
      • TABLE 8 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY: TOP 20 SPENDERS, 2016 (%)
      • FIGURE 3 HEALTH EXPENDITURES AS PERCENT OF GDP BY COUNTRY: TOP 20 SPENDERS, 2016 (%)
      • Trends in Hospital Length of Stay
      • TABLE 9 HOSPITAL USAGE STATISTICS, 2005 COMPARED WITH 2015 (DAYS)
      • FIGURE 4 HOSPITAL USAGE STATISTICS, 2005 AND 2015 (DAYS)
    • PUBLIC HEALTHCARE SYSTEMS AROUND THE WORLD
    • TABLE 10 WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50, 2010
    • GLOBAL SHORTAGE OF HEALTHCARE WORKERS
    • TECHNOLOGICAL ADVANCEMENT
      • Availability-Ease of Use Devices
      • New Technologies
    • INCIDENCE OF DISEASE
    • TABLE 11 STATISTICS OF SELECTED DISEASES IN THE GLOBAL POPULATION, 2016 ESTIMATES
      • Asthma
      • Cardiovascular Disease
      • Cancer
      • Diabetes
      • Diarrheal Disease
      • HIV
      • Infertility
      • Influenza
      • Malaria
      • Pregnancy
      • TABLE 12 BIRTH RATES AND BIRTHS BY COUNTRY, 2016 ESTIMATES (THOUSAND/%)
      • FIGURE 5 BIRTH RATES AND BIRTHS BY COUNTRY, 2016 ESTIMATES (THOUSAND/%)
      • Tuberculosis
      • ATTENTION TO DRUGS OF ABUSE
    • DEMOGRAPHICS AND AGING POPULATIONS
      • Global Demographics
      • TABLE 13 ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
      • FIGURE 6 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)
      • TABLE 14 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
      • FIGURE 7 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)
      • Global Life Expectancy
      • TABLE 15 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
      • FIGURE 8 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
      • U.S. Demographics
      • TABLE 16 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 1900-2050 (THOUSANDS)
      • FIGURE 9 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 1900 TO 2050 (THOUSANDS)
        • Gender, Age and Life Expectancy
        • TABLE 17 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY SEX, 1990-2020 (YEARS)
        • FIGURE 10 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY SEX, 1990-2020 (YEARS)
        • TABLE 18 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2015 (YEARS)
        • FIGURE 11 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2015 (YEARS)

CHAPTER 4 THE GLOBAL POC MARKET

  • MARKET OVERVIEW
  • TABLE 19 GLOBAL FORECAST FOR THE POC MARKET BY TEST TYPE, THROUGH 2021 ($ MILLIONS)
  • FIGURE 12 GLOBAL FORECAST FOR THE POC MARKET BY TEST TYPE, 2016 AND 2021 ($ MILLIONS)
  • FIGURE 13 DISTRIBUTION OF SALES FOR THE GLOBAL POC MARKET BY TEST TYPE, 2016 (%)
  • COMPETITOR MARKET SHARE
  • TABLE 20 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2016 (%)
  • FIGURE 14 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2016 (%)
  • MARKET STRUCTURE
    • DISTRIBUTION
    • FIGURE 15 DISTRIBUTION CHANNELS: POC DIAGNOSTIC DEVICES
    • PROMOTION
    • STRATEGIC ALLIANCES AND MERGERS
  • MARKET COMPONENTS
    • BLOOD CHEMISTRY AND ELECTROLYTE TESTING
    • CARDIAC MARKER TESTING
    • CHOLESTEROL TESTING
    • DRUG AND ALCOHOL ABUSE TESTING
    • GLUCOSE TESTING
    • INFECTIOUS DISEASE TESTING
    • PREGNANCY AND FERTILITY TESTING
    • HEMATOLOGY AND HEMOSTASIS TESTING
    • TUMOR MARKER TESTING
    • URINE CHEMISTRY TESTING
    • MISCELLANEOUS POC TESTING

CHAPTER 5 BLOOD CHEMISTRY AND ELECTROLYTE TESTING

  • SEGMENT OVERVIEW
  • BLOOD CHEMISTRY PARAMETERS
    • ELECTROLYTES
    • CLIA Quality Control Requirements for Blood Gas Analysis
  • MARKET SIZE
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 21 RELATIVE MARKET SHARE OF POC BLOOD CHEMISTRY ANALYZER MANUFACTURERS, 2016 (%)
  • FIGURE 16 RELATIVE MARKET OF SHARE BLOOD GAS ANALYZER MANUFACTURERS, 2016 (%)
    • ABBOTT DIAGNOSTICS
      • i-STAT
    • ABAXIS
      • Piccolo Classic and Piccolo Xpress
      • TABLE 22 ABAXIS PICCOLO ANALYZER TEST AVAILABILITY
    • ALERE
      • Epoc Blood Analysis System
    • INTERNATIONAL TECHNIDYNE CORP.
      • IRMA TRUpoint Blood Analysis System
      • AVOXimeter Whole Blood CO-Oximeter/Oximeter System
    • NOVA BIOMEDICAL
      • Stat Profile pHOx Product Line
      • TABLE 23 NOVA BIOCHEMICAL POC STAT PROFILE PHOX SERIES BY AVAILABLE TESTS
    • RADIOMETER AMERICA INC.
      • ABL80, ABL90 FLEX, ABL800 FLEX
    • ROCHE DIAGNOSTICS
      • Cobas b 121 System
      • Cobas b 221 Blood Gas System
    • SIEMENS HEALTHCARE
      • Rapidpoint 400/405
      • RAPIDComm Data Management System

CHAPTER 6 CARDIAC MARKER TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 24 RELATIVE MARKET SHARE OF POC CARDIAC MARKER MANUFACTURERS, 2016 (%)
  • FIGURE 17 RELATIVE MARKET SHARE OF POC CARDIAC MARKER MANUFACTURERS, 2016 (%)
    • ABBOTT
      • iSTAT 1
    • ALERE
      • Triage System
      • Triage BNP Test
      • Heart Check System
    • ROCHE
      • Cobas h 232 System
    • RESPONSE BIOMEDICAL
      • RAMP System
    • SIEMENS
      • Stratus CS Acute Care Diagnostic System

CHAPTER 7 CHOLESTEROL TESTING

  • SEGMENT OVERVIEW
    • MARKET SIZE
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 25 RELATIVE MARKET SHARE OF CHOLESTEROL POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 18 RELATIVE MARKET SHARE OF CHOLESTEROL POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 26 CLIA-WAIVED APPROVED CHOLESTEROL TESTS, 2015-2016
    • ABAXIS
    • ALERE
    • ROCHE DIAGNOSTICS

CHAPTER 8 DRUG AND ALCOHOL ABUSE TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 27 RELATIVE MARKET SHARE OF DRUG AND ALCOHOL POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 19 RELATIVE MARKET SHARE OF DRUG AND ALCOHOL POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 28 CLIA-WAIVED APPROVED POC DRUG AND ALCOHOL SCREENING TESTS, 2015-2016
    • ALERE
    • ORASURE TECHNOLOGIES
    • PHAMATECH

CHAPTER 9 GLUCOSE TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 29 RELATIVE MARKET SHARE FOR GLUCOSE METERS AND SUPPLIES MANUFACTURERS, 2016 (%)
  • FIGURE 20 RELATIVE MARKET SHARE FOR GLUCOSE METERS AND SUPPLIES MANUFACTURERS, 2016 (%)
  • TABLE 30 CLIA-WAIVED APPROVED BLOOD GLUCOSE METERS, 2015-2016
  • TABLE 31 CLIA-WAIVED APPROVED BLOOD GLUCOSE METERS, 2013 AND PRIOR
    • ROCHE DIAGNOSTICS
      • Accu-Chek Nano Meter System
      • Accu-Chek Aviva Meter System
      • Accu-Chek Compact Plus Meter System
      • Accu-Chek Active System
      • Accu-Chek Inform System
      • Accu-Chek Inform II
      • Accu-Chek Voicemate System
    • JOHNSON AND JOHNSON
      • LifeScan-OneTouch Ultra 2 Meter
      • LifeScan-OneTouch UltraMini
      • LifeScan-OneTouch Verio and Verio IQ
      • LifeScan-OneTouch Ultra Meter
      • LifeScan OneTouch InDuo System
      • LifeScan OneTouch Basic Meter
      • LifeScan OneTouch SureStep Meter
      • LifeScan OneTouch UltraLink Meter
      • LifeScan OneTouch Diabetes Management Software
    • ABBOTT DIABETES CARE
      • FreeStyle Blood Glucose Monitoring System
      • Precision Blood Glucose and Ketone Monitoring Systems
      • i-STAT 1
    • TREVIDIA HEALTH
      • Sidekick Testing System
      • TrueTrack Smart System
    • SIEMENS
      • DCA Vantage Analyzer
      • Home Diagnostic Meters-Retailers
      • TABLE 32 SELECTED LISTING OF RETAILERS SELLING HOME DIAGNOSTIC METERS
      • Data Management Systems
      • TABLE 33 SELECT LISTING OF BLOOD GLUCOSE MONITORS CAPABLE OF INTERACTING WITH COMPUTER SOFTWARE

CHAPTER 10 INFECTIOUS DISEASE TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • TABLE 34 ESTIMATED MARKET SHARE FOR THE GLOBAL POC INFECTIOUS DISEASE MARKET BY TEST TYPE, 2016 (%)
  • FIGURE 21 ESTIMATED MARKET SHARE FOR THE GLOBAL POC INFECTIOUS DISEASE MARKET BY TEST TYPE, 2016 (%)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 35 RELATIVE MARKET SHARE OF INFECTIOUS DISEASE POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 22 RELATIVE MARKET SHARE OF INFECTIOUS DISEASE POC RAPID TEST MANUFACTURERS, 2016 (%)
    • STREP A
    • INFLUENZA
    • CHLAMYDIA
    • SPECIFIC PRODUCTS FOR TESTING
      • Strep A
      • TABLE 36 CLIA-WAIVED APPROVED POC INFECTIOUS DISEASE TESTS, 2015-2016
      • TABLE 37 CLIA-WAIVED APPROVED STREP A TESTS, 2013 AND PRIOR
        • Alere Inc.
        • Beckman Coulter
        • BTNX Inc.
        • Quidel
      • Influenza
      • TABLE 38 CLIA-WAIVED APPROVED INFLUENZA TESTS
        • Alere Inc.
        • Becton Dickinson
        • OraSure Technologies
        • Quidel
        • SA Scientific
      • Chlamydia/Trichomoniasis
      • TABLE 39 CLIA-WAIVED APPROVED CHLAMYDIA/TRICHOMONAS TEST
        • Quidel
        • Sekisui Diagnostics
      • RSV
      • TABLE 40 CLIA-WAIVED APPROVED RSV TESTS
        • Alere
        • BTNX Inc.
        • Quidel
      • HIV Testing
      • TABLE 41 CLIA-WAIVED APPROVED HIV TESTS
        • Alere Inc.
        • OraSure Technologies
        • Trinity Biotech plc
      • Infectious Mononucleosis
      • TABLE 42 CLIA-WAIVED APPROVED INFECTIOUS MONONUCLEOSIS TESTS
        • Beckman Coulter
        • Quidel
      • H. pylori
      • TABLE 43 CLIA-WAIVED APPROVED H. PYLORI TESTS
        • Quidel
      • Herpes Simplex Virus
        • Trinity Biotech
      • Syphilis Treponemal
        • Trinity Biotech
      • Hepatitis C Virus
      • TABLE 44 CLIA-WAIVED APPROVED HCV TESTS
      • S. Pneumoniae
        • Trinity Biotech
      • Adenovirus
      • TABLE 45 CLIA-WAIVED APPROVED ADENOVIRUS TEST

CHAPTER 11 PREGNANCY AND FERTILITY TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • TABLE 46 MARKET SHARE FOR THE GLOBAL POC PREGNANCY/FERTILITY MARKET BY TEST TYPE, 2016 (%)
  • FIGURE 23 MARKET SHARE FOR THE GLOBAL POC PREGNANCY/FERTILITY MARKET BY TEST TYPE, 2016 (%)
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 47 RELATIVE MARKET SHARE OF PREGNANCY/FERTILITY POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 24 RELATIVE MARKET SHARE OF PREGNANCY/FERTILITY POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 48 CLIA-WAIVED APPROVED POC PREGNANCY TESTS, 2015-2016
  • TABLE 49 CLIA-WAIVED APPROVED PREGNANCY TESTS, 2013 AND PRIOR

CHAPTER 12 HEMOGLOBIN/HEMOSTASIS TESTING

  • HEMATOLOGY AND HEMOSTASIS
  • HEMOSTASIS (COAGULATION)
  • MARKET SIZE
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 50 RELATIVE MARKET SHARE OF HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 25 RELATIVE MARKET SHARE OF HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 51 CLIA-WAIVED APPROVED POC HEMATOLOGY TESTS, 2015-2016
  • TABLE 52 CLIA-WAIVED APPROVED HEMATOLOGY TESTS, 2013 AND PRIOR
    • ALERE
    • ROCHE

CHAPTER 13 TUMOR MARKER TESTING

  • SEGMENT OVERVIEW
  • FECAL AND GASTRIC OCCULT BLOOD
  • BLADDER TUMOR ANTIGEN TEST
  • MARKET SIZE
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 53 RELATIVE MARKET SHARE OF TUMOR MARKER POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 26 RELATIVE MARKET SHARE OF TUMOR MARKER POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 54 CLIA-WAIVED APPROVED POC FECAL OCCULT BLOOD TESTS, 2015-2016
  • TABLE 55 CLIA-WAIVED APPROVED FECAL OCCULT BLOOD TESTS, 2013 AND PRIOR
    • BECKMAN COULTER
    • QUIDEL
    • TABLE 56 CLIA-WAIVED APPROVED BLADDER TESTS
    • ALERE

CHAPTER 14 URINE CHEMISTRY TESTING

  • SEGMENT OVERVIEW
  • MARKET SIZE
  • MARKET PARTICIPANTS AND MARKET SHARES
  • TABLE 57 RELATIVE MARKET SHARE OF POC URINE CHEMISTRY ANALYZER MANUFACTURERS, 2016 (%)
  • FIGURE 27 RELATIVE MARKET SHARE OF POC URINE CHEMISTRY ANALYZER MANUFACTURERS, 2016 (%)
  • TABLE 58 CLIA-WAIVED APPROVED POC URINE CHEMISTRY TESTS AND ANALYZERS TESTS, 2015-2016
  • TABLE 59 CLIA-WAIVED APPROVED URINE CHEMISTRY TESTS AND ANALYZERS, 2013 AND PRIOR
    • SIEMENS

CHAPTER 15 OTHER POC TESTING

  • MARKET SIZE
  • SEGMENT OVERVIEW
    • VAGINAL PH TESTS
    • TABLE 60 CLIA-WAIVED APPROVED VAGINAL PH TEST
    • THYROID STIMULATING HORMONE TESTS
    • TABLE 61 CLIA-WAIVED APPROVED TSH TESTS
    • MALE REPRODUCTIVE TESTS
    • TABLE 62 CLIA-WAIVED APPROVED MALE REPRODUCTIVE TEST
    • MENOPAUSE
    • TABLE 63 CLIA-WAIVED APPROVED MENOPAUSE TEST
    • DRY EYE
    • TABLE 64 CLIA-WAIVED APPROVED DRY EYE TEST

CHAPTER 16 TECHNOLOGY APPLICATIONS

  • INTRODUCTION
  • ELECTRONIC DATA MANAGEMENT INTEGRATION
    • POC DEVICE CASE STUDIES-SIEMENS HEALTHCARE
    • ABBOTT I-STAT AND HEALTH RECORDS
  • BIOSENSORS
    • WHAT ARE BIOSENSORS?
      • Catalytic Sensors
      • Affinity Sensors
  • ELECTRODES
    • WHAT ARE ELECTRODES?
  • CONTINUOUS TESTING
    • OCCLUSION SPECTROSCOPY
    • TRANSDERMAL ALCOHOL CONTINUOUS TESTING
    • NONINVASIVE ELECTRONIC SKIN SENSORS
  • RAPID HIV TESTS
    • CHEMBIO DIAGNOSTIC SYSTEMS INC.
  • RAPID CLINICAL DRUG TESTING
    • PSYCHEMEDICS CORP.
    • TEARLAB CORP'S OSMOLARITY SYSTEM
    • PATENT ANALYSIS
    • NUMBER OF RECENTLY ISSUED PATENTS
    • TABLE 65 SELECTED U.S. PATENTS FOR POC DIAGNOSTIC TESTING, JANUARY 2014 TO JULY 2016
      • Glucose
      • TABLE 66 U.S. PATENTS FOR POC DIAGNOSTIC GLUCOSE TESTING, JANUARY 2014 TO JULY 2016
      • Blood chemistry and Electrolyte
      • Pregnancy and Fertility
      • TABLE 67 U.S. PATENT FOR POC DIAGNOSTIC PREGNANCY TESTING, JANUARY 2014 TO JULY 2016
      • Infectious Disease
      • TABLE 68 U.S. PATENTS FOR POC DIAGNOSTIC INFECTIOUS DISEASE TESTING, JANUARY 2014 TO JULY 2016
      • Cholesterol
      • TABLE 69 U.S. PATENT FOR POC DIAGNOSTIC CHOLESTEROL TESTING, JANUARY 2014 TO JULY 2016
      • Urine
      • TABLE 70 U.S. PATENTS FOR POC DIAGNOSTIC URINE TESTING, JANUARY 2014 TO JULY 2016
    • SELECTED PATENT ASSIGNEES
      • Abbott Laboratories
      • AccuVein Inc.
      • Panasonic Corp.
      • Roche Diagnostics Operations Inc.

CHAPTER 17 GLOBAL POC MARKET

  • INTERNATIONAL MARKET SIZE
  • TABLE 71 GLOBAL POC MARKET, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • FIGURE 28 GLOBAL POC MARKET, BY SEGMENT, 2014-2021 ($ MILLIONS)
  • GLOBAL MARKET SHARES
  • TABLE 72 GLOBAL POC MARKET SHARE, BY REGION, 2016 (%/$ MILLIONS)
  • FIGURE 29 NORTH AMERICAN POC MARKET SHARE, BY REGION, 2016 (%)
  • TABLE 73 NORTH AMERICAN POC MARKET, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • FIGURE 30 EUROPEAN POC MARKET SHARE, BY COUNTRY, 2016 (%)
  • TABLE 74 EUROPEAN POC MARKET, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • FIGURE 31 ASIAN POC MARKET SHARE, BY COUNTRY, 2016 (%)
  • TABLE 75 ASIAN POC MARKET, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 76 REST OF THE WORLD POC MARKET, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • PRESENCE OF MANUFACTURERS IN THE WORLDWIDE MARKET
  • TABLE 77 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2016 (%)
  • FIGURE 32 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2016 (%)

CHAPTER 18 PROFILES OF MAJOR MARKET PARTICIPANTS

  • OVERVIEW OF MARKET PARTICIPANTS
  • COMPANY PROFILES
    • ABAXIS INC.
    • ABBOTT LABORATORIES
    • ALERE INC.
    • BECKMAN COULTER INC.
    • BECTON, DICKINSON AND CO.
    • CHEMBIO DIAGNOSTICS INC.
    • CHURCH & DWIGHT CO. INC.
    • DANAHER CORP.
    • HEMOCUE AB
    • INTERNATIONAL TECHNIDYNE CORP.
    • JOHNSON & JOHNSON
    • NOVA BIOMEDICAL
    • ORASURE TECHNOLOGIES
      • Infectious Disease
      • Molecular Collectionand Stabilization
      • Substance Abuse/Insurance Risk Assessment
    • PHAMATECH INC.
    • QUIDEL CORP.
    • RADIOMETER MEDICAL APS
    • ROCHE
    • TABLE 78 ROCHE'S RECENT ACQUISITIONS, 2014-2016
    • SA SCIENTIFIC LTD.
    • SEKISUI DIAGNOSTICS
    • SIEMENS MEDICAL SOLUTIONS
      • POC Products and Solutions:
    • TRIVIDIA HEALTH INC.
    • TRINITY BIOTECH PLC

CHAPTER 19 APPENDIX

  • KEY SOURCES OF INFORMATION
    • ABAXIS, INC
    • ABBOTT LABORATORIES
    • ACON LABORATORIES INC.
    • ALERE INC.
    • ALFA SCIENTIFIC DESIGNS INC.
    • ARKRAY INC. KYOTO MIYUKI BLDG. 10F
    • BECKMAN COULTER INC.
    • BECTON, DICKINSON AND CO.
    • BIOMERICA INC.
    • BTNX INC.
    • CHURCH & DWIGHT CO. INC.
    • CLIAWAIVED.COM
    • COAGUSENSE INC.
    • DANAHER CORP.
    • EKF DIAGNOSTICS COMPANY
    • FORA CARE INC.
    • HEMOCUE AB
    • INSIGHT PHARMACEUTICALS LLC.
    • INTERNATIONAL TECHNIDYNE CORP.
    • JANT PHARMACAL CORP.
    • JOHNSON & JOHNSON
    • MERIDIAN BIOSCIENCE INC.
    • NOVA BIOMEDICAL
    • ORASURE TECHNOLOGIES
    • PHAMATECH INC.
    • PRINCETON BIOMEDITECH CORP.
    • QUEST DIAGNOSTICS
    • QUIDEL CORP.
    • RADIOMETER MEDICAL APS
    • RESPONSE BIOMEDICAL CORP.
    • ROCHE
    • SA SCIENTIFIC LTD.
    • SEKISUI DIAGNOSTICS
    • SIEMENS MEDICAL SOLUTIONS
    • SPECTRAL DIAGNOSTICS
    • STANBIO LABORATORY
    • SWISS PRECISION DIAGNOSTICS GMBH
    • TREVIDIA HEALTH INC.
    • TRINITY BIOTECH PLC

LIST OF TABLES

  • SUMMARY TABLE GLOBAL POC MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 1 SELECTED KEY STATISTICS FOR POC TESTING SITES
  • TABLE 2 ESTIMATED NUMBER OF HOSPITALS/INPATIENT ACUTE CARE CENTERS AND BEDS AVAILABLE BY SELECTED COUNTRY, 2016
  • TABLE 3 ESTIMATED NURSING HOMES RESIDENTS BY SELECTED U.S. STATES, 2016 (NO./%)
  • TABLE 4 HOSPICE FACTS, 2016 ESTIMATED
  • TABLE 5 SELECTED POC TESTS-CLIA WAIVED
  • TABLE 6 PERTINENT PARAMETERS OF GMP REGULATIONS AFFECTING IN VITRO DIAGNOSTICS
  • TABLE 7 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY SELECT COUNTRY. 1980-2015 (%)
  • TABLE 8 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY: TOP 20 SPENDERS, 2016 (%)
  • TABLE 9 HOSPITAL USAGE STATISTICS, 2005 COMPARED WITH 2015 (DAYS)
  • TABLE 10 WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50, 2010
  • TABLE 11 STATISTICS OF SELECTED DISEASES IN THE GLOBAL POPULATION, 2016 ESTIMATES
  • TABLE 12 BIRTH RATES AND BIRTHS BY COUNTRY, 2016 ESTIMATES (THOUSAND/%)
  • TABLE 13 ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
  • TABLE 14 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
  • TABLE 15 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
  • TABLE 16 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 1900-2050 (THOUSANDS)
  • TABLE 17 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY SEX, 1990-2020 (YEARS)
  • TABLE 18 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2015 (YEARS)
  • TABLE 19 GLOBAL FORECAST FOR THE POC MARKET BY TEST TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 20 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2016 (%)
  • TABLE 21 RELATIVE MARKET SHARE OF POC BLOOD CHEMISTRY ANALYZER MANUFACTURERS, 2016 (%)
  • TABLE 22 ABAXIS PICCOLO ANALYZER TEST AVAILABILITY
  • TABLE 23 NOVA BIOCHEMICAL POC STAT PROFILE PHOX SERIES BY AVAILABLE TESTS
  • TABLE 24 RELATIVE MARKET SHARE OF POC CARDIAC MARKER MANUFACTURERS, 2016 (%)
  • TABLE 25 RELATIVE MARKET SHARE OF CHOLESTEROL POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 26 CLIA-WAIVED APPROVED CHOLESTEROL TESTS, 2015-2016
  • TABLE 27 RELATIVE MARKET SHARE OF DRUG AND ALCOHOL POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 28 CLIA-WAIVED APPROVED POC DRUG AND ALCOHOL SCREENING TESTS, 2015-2016
  • TABLE 29 RELATIVE MARKET SHARE FOR GLUCOSE METERS AND SUPPLIES MANUFACTURERS, 2016 (%)
  • TABLE 30 CLIA-WAIVED APPROVED BLOOD GLUCOSE METERS, 2015-2016
  • TABLE 31 CLIA-WAIVED APPROVED BLOOD GLUCOSE METERS, 2013 AND PRIOR
  • TABLE 32 SELECTED LISTING OF RETAILERS SELLING HOME DIAGNOSTIC METERS
  • TABLE 33 SELECT LISTING OF BLOOD GLUCOSE MONITORS CAPABLE OF INTERACTING WITH COMPUTER SOFTWARE
  • TABLE 34 ESTIMATED MARKET SHARE FOR THE GLOBAL POC INFECTIOUS DISEASE MARKET BY TEST TYPE, 2016 (%)
  • TABLE 35 RELATIVE MARKET SHARE OF INFECTIOUS DISEASE POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 36 CLIA-WAIVED APPROVED POC INFECTIOUS DISEASE TESTS, 2015-2016
  • TABLE 37 CLIA-WAIVED APPROVED STREP A TESTS, 2013 AND PRIOR
  • TABLE 38 CLIA-WAIVED APPROVED INFLUENZA TESTS
  • TABLE 39 CLIA-WAIVED APPROVED CHLAMYDIA/TRICHOMONAS TEST
  • TABLE 40 CLIA-WAIVED APPROVED RSV TESTS
  • TABLE 41 CLIA-WAIVED APPROVED HIV TESTS
  • TABLE 42 CLIA-WAIVED APPROVED INFECTIOUS MONONUCLEOSIS TESTS
  • TABLE 43 CLIA-WAIVED APPROVED H. PYLORI TESTS
  • TABLE 44 CLIA-WAIVED APPROVED HCV TESTS
  • TABLE 45 CLIA-WAIVED APPROVED ADENOVIRUS TEST
  • TABLE 46 MARKET SHARE FOR THE GLOBAL POC PREGNANCY/FERTILITY MARKET BY TEST TYPE, 2016 (%)
  • TABLE 47 RELATIVE MARKET SHARE OF PREGNANCY/FERTILITY POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 48 CLIA-WAIVED APPROVED POC PREGNANCY TESTS, 2015-2016
  • TABLE 49 CLIA-WAIVED APPROVED PREGNANCY TESTS, 2013 AND PRIOR
  • TABLE 50 RELATIVE MARKET SHARE OF HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 51 CLIA-WAIVED APPROVED POC HEMATOLOGY TESTS, 2015-2016
  • TABLE 52 CLIA-WAIVED APPROVED HEMATOLOGY TESTS, 2013 AND PRIOR
  • TABLE 53 RELATIVE MARKET SHARE OF TUMOR MARKER POC RAPID TEST MANUFACTURERS, 2016 (%)
  • TABLE 54 CLIA-WAIVED APPROVED POC FECAL OCCULT BLOOD TESTS, 2015-2016
  • TABLE 55 CLIA-WAIVED APPROVED FECAL OCCULT BLOOD TESTS, 2013 AND PRIOR
  • TABLE 56 CLIA-WAIVED APPROVED BLADDER TESTS
  • TABLE 57 RELATIVE MARKET SHARE OF POC URINE CHEMISTRY ANALYZER MANUFACTURERS, 2016 (%)
  • TABLE 58 CLIA-WAIVED APPROVED POC URINE CHEMISTRY TESTS AND ANALYZERS TESTS, 2015-2016
  • TABLE 59 CLIA-WAIVED APPROVED URINE CHEMISTRY TESTS AND ANALYZERS, 2013
  • AND PRIOR
  • TABLE 60 CLIA-WAIVED APPROVED VAGINAL PH TEST
  • TABLE 61 CLIA-WAIVED APPROVED TSH TESTS
  • TABLE 62 CLIA-WAIVED APPROVED MALE REPRODUCTIVE TEST
  • TABLE 63 CLIA-WAIVED APPROVED MENOPAUSE TEST
  • TABLE 64 CLIA-WAIVED APPROVED DRY EYE TEST
  • TABLE 65 SELECTED U.S. PATENTS FOR POC DIAGNOSTIC TESTING, JANUARY 2014 TO JULY 2016
  • TABLE 66 U.S. PATENTS FOR POC DIAGNOSTIC GLUCOSE TESTING, JANUARY 2014 TO JULY 2016
  • TABLE 67 U.S. PATENT FOR POC DIAGNOSTIC PREGNANCY TESTING, JANUARY 2014 TO JULY 2016
  • TABLE 68 U.S. PATENTS FOR POC DIAGNOSTIC INFECTIOUS DISEASE TESTING, JANUARY 2014 TO JULY 2016
  • TABLE 69 U.S. PATENT FOR POC DIAGNOSTIC CHOLESTEROL TESTING, JANUARY 2014 TO JULY 2016
  • TABLE 70 U.S. PATENTS FOR POC DIAGNOSTIC URINE TESTING, JANUARY 2014 TO JULY 2016
  • TABLE 71 GLOBAL POC MARKET, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 72 GLOBAL POC MARKET SHARE, BY REGION, 2016 (%/$ MILLIONS)
  • TABLE 73 NORTH AMERICAN POC MARKET, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 74 EUROPEAN POC MARKET, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 75 ASIAN POC MARKET, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 76 REST OF THE WORLD POC MARKET, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 77 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2016 (%)
  • TABLE 78 ROCHE'S RECENT ACQUISITIONS, 2014-2016

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL POC MARKET, BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 1 ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE BEDS BY SELECTED COUNTRY, 2016
  • FIGURE 2 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY SELECT COUNTRY, 1980-2015 (%)
  • FIGURE 3 HEALTH EXPENDITURES AS PERCENT OF GDP BY COUNTRY: TOP
  • SPENDERS, 2016 (%)
  • FIGURE 4 HOSPITAL USAGE STATISTICS, 2005 AND 2015 (DAYS)
  • FIGURE 5 BIRTH RATES AND BIRTHS BY COUNTRY, 2016 ESTIMATES (THOUSAND/%)
  • FIGURE 6 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)
  • FIGURE 7 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)
  • FIGURE 8 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)
  • FIGURE 9 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 1900 TO 2050 (THOUSANDS)
  • FIGURE 10 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY SEX, 1990-2020 (YEARS)
  • FIGURE 11 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2015 (YEARS)
  • FIGURE 12 GLOBAL FORECAST FOR THE POC MARKET BY TEST TYPE, 2016 AND 2021 ($ MILLIONS)
  • FIGURE 13 DISTRIBUTION OF SALES FOR THE GLOBAL POC MARKET BY TEST TYPE, 2016 (%)
  • FIGURE 14 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2016 (%)
  • FIGURE 15 DISTRIBUTION CHANNELS: POC DIAGNOSTIC DEVICES
  • FIGURE 16 RELATIVE MARKET OF SHARE BLOOD GAS ANALYZER MANUFACTURERS, 2016 (%)
  • FIGURE 17 RELATIVE MARKET SHARE OF POC CARDIAC MARKER MANUFACTURERS, 2016 (%)
  • FIGURE 18 RELATIVE MARKET SHARE OF CHOLESTEROL POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 19 RELATIVE MARKET SHARE OF DRUG AND ALCOHOL POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 20 RELATIVE MARKET SHARE FOR GLUCOSE METERS AND SUPPLIES MANUFACTURERS, 2016 (%)
  • FIGURE 21 ESTIMATED MARKET SHARE FOR THE GLOBAL POC INFECTIOUS DISEASE MARKET BY TEST TYPE, 2016 (%)
  • FIGURE 22 RELATIVE MARKET SHARE OF INFECTIOUS DISEASE POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 23 MARKET SHARE FOR THE GLOBAL POC PREGNANCY/FERTILITY MARKET BY TEST TYPE, 2016 (%)
  • FIGURE 24 RELATIVE MARKET SHARE OF PREGNANCY/FERTILITY POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 25 RELATIVE MARKET SHARE OF HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 26 RELATIVE MARKET SHARE OF TUMOR MARKER POC RAPID TEST MANUFACTURERS, 2016 (%)
  • FIGURE 27 RELATIVE MARKET SHARE OF POC URINE CHEMISTRY ANALYZER MANUFACTURERS, 2016 (%)
  • FIGURE 28 GLOBAL POC MARKET, BY SEGMENT, 2014-2021 ($ MILLIONS)
  • FIGURE 29 NORTH AMERICAN POC MARKET SHARE, BY REGION, 2016 (%)
  • FIGURE 30 EUROPEAN POC MARKET SHARE, BY COUNTRY, 2016 (%)
  • FIGURE 31 ASIAN POC MARKET SHARE, BY COUNTRY, 2016 (%)
  • FIGURE 32 MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2016 (%)
Back to Top